Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Intellect and MRCT Announces Complete Humanization of 82E1

Published: Friday, September 21, 2012
Last Updated: Friday, September 21, 2012
Bookmark and Share
MRCT amends agreement increasing its shared risk in development of humanized antibody.

Intellect Neurosciences, Inc. and MRC Technology (MRCT) have announced that they have completed humanization of 82E1, a mouse monoclonal antibody to create a high-affinity stabilized IgG4 therapeutic antibody that binds the amino terminus of amyloid beta without binding to the amyloid precursor protein (APP).

Antibodies exist in several isoforms; IgG1 antibodies have the strongest potential to induce inflammation while IgG4 has the lowest potential.

The Intellect antibody, called IN-N01, is anticipated to promote the clearance of monomeric, oligomeric and plaque forms of amyloid beta, which accumulate in the brains of Alzheimer's patients or following traumatic brain injury and in the retina of the eye in patients with age-related macular degeneration, diabetic neuropathy and glaucoma.

Intellect Neurosciences and MRCT also have amended their Service Agreement to reduce Intellect’s cash outlay in exchange for equity. This reflects MRCT’s new strategy of risk sharing on exciting antibody projects.

“IN-N01 is an important addition to Intellect’s diversified preclinical pipeline,” commented Daniel G. Chain, PhD, Intellect’s Chairman and CEO.

Chain continued, “The recent Phase 3 data for bapineuzumab, an IgG1 antibody, despite failing to show improvement in clinical endpoints, demonstrated through the use of biomarkers the drug engaged the amyloid beta target and reduced neurodegeneration indicating both the need for earlier intervention and improved antibody-based therapies. We anticipate IN-N01 will have improved safety, which means that it can be used at higher, more frequent doses, that likely will result in clinical efficacy, especially if administered to presymptomatic patients.”

IN-N01 could be developed without further modification or empowered by chemically combining the antibody with a small molecule, such as an antioxidant, using Intellect’s CONJUMAB™ platform technology.

The company plans to evaluate IN-N01 in both contexts. Additionally, Intellect plans to test IN-N01 in combination with its tau monoclonal antibodies, TOC1- and TauC3.

“MRCT’s collaboration with the team at Intellect Neurosciences applying our unparalleled expertise to this important and timely project will be critical to the development of IN-N01 as a therapeutic antibody and we are confident in its potential success,” said Dr. Dave Tapolczay, MRCT’s CEO.

Dr. Tapolczay continued, “We believe Intellect Neurosciences is on track with a promising drug candidate and therefore were pleased to offset their cost of development by sharing in the risk.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos